Overview
HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of promising companies.
Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).
The fund’s website can be found here.
SIX:HBMN : HBM Healthcare Investments
News
-
28 Aug 2018 1 min read
HBM-backed Y-mAbs files for US IPO
Swiss-listed HBM Healthcare (HBMN) may see a gain from its investment in the private Danish company Y-mAbs Therapeutics, which has filed an S1 registration to raise up to $92m in a Nasdaq IPO. HBM has an 8.2% shareholding in Y-mAbs, which it valued at CHF23m (1.9% of NAV) in its accounts – suggesting the company currently has a CHF280m […]
-
22 Aug 2018 1 min read
AbbVie exercises option for HBM-backed Argenx antibody
AbbVie exercises option for HBM-backed Argenx antibody Dutch/Belgian antibody company Argenx (Euronext & Nasdaq: ARGX), a top ten holding for Swiss-listed HBM Healthcare (HBMN, 2.6% of NAV) has disclosed that AbbVie has taken up its option to licence the preclinical stage immuno-oncology product ARGX-115. Argenx and AbbVie, a US based pharmaceutical major, entered into an option deal covering ARGX-115 in April […]
-
16 Aug 2018 2 min read
HBM-backed Argenx has biotech industry’s most valuable unpartnered R&D asset
HBM-backed Argenx has biotech industry’s most valuable unpartnered R&D asset Dutch/Belgian antibody company Argenx (Euronext & Nasdaq:ARGX), a top ten holding for Swiss-listed HBM Healthcare (HBMN, 2.9% of NAV), has the biotech industry’s most valuable unpartnered R&D asset in the form of its lead compound efgartigimod for myasthenia gravis and other autoimmune diseases, according to industry […]
-
03 Aug 2018 1 min read
Tekla Healthcare top specialist fund performer in July
Tekla Healthcare top specialist fund performer in July Tekla Healthcare Opportunities, a US closed end fund that invests largely in US large cap pharma and biotech, saw the best investment performance of the 14 specialist biotech specialist investors monitored by Marten & Co, in terms of its sterling-adjusted NAV performance for the month of July. Switzerland’s BB […]
-
02 Aug 2018 2 min read
HBM sees best share price performance in YTD period
HBM sees best share price performance in YTD period London-listed HBM Healthcare (HBMN) recorded the best share price price performance so far this year of the 14 biotech specialist investment trusts monitored by Marten & Co, with a 25% rise in the seven months to end July. HBM’s share price outstripped growth in NAV, which […]
-
18 Jul 2018 2 min read
FDA accepts HBM investee Immunomedics’ breast cancer drug filing
FDA accepts HBM investee Immunomedics’ breast cancer drug filing US biotech Immunomedics (Nasdaq:IMMU), a top 10 holding for Swiss-listed HBM Healthcare (2.5% of NAV), has reported that the US FDA has accepted its regulatory application for the antibody-drug conjugate sacituzumab govitecan and granted priority review with an action date of 18 January 2019. The application […]
-
28 Jun 2018 1 min read
HBM gains on IPO of investee Aptinyx
HBM gains on IPO of investee Aptinyx HBM Healthcare (HBMN) should be able to see a ~CHF15m gain in NAV, following the IPO of investee company Aptinyx on Nasdaq earlier this week and the 40% rise in its stock price since. Aptinyx (Nasdaq: APTX) raised gross proceeds of $118m from the sale of 7.4m shares at […]
-
29 May 2018 2 min read
Trust favourite Genmab hit by trial setback
Trust favourite Genmab hit by trial setback Denmark’s Genmab, a widely-held stock among the sector specialist investment trusts, has suffered a major setback in the past week with failure/termination of studies involving its lead product Darzalex, which is sold by Johnson & Johnson. The studies were both aimed at expanding the range of uses of Darzalex, […]
-
21 May 2018 2 min read
HBM boosts dividend by 20% after stellar year
HBM boosts dividend by 20% after stellar year London-listed HBM Healthcare (HBMN) has proposed a CHF 7/share dividend for year to end April, a 20% rise, after a strong year in which it saw a 11% rise in NAV and 34% rise in share price, beating the broadest biotech index and all other sector specialist […]
-
10 May 2018 2 min read
HBM set to gain on Lilly buyout of investee Armo
HBM set to gain on Lilly buyout of investee Armo Swiss-listed HBM Healthcare (HBMN) looks set to see a significant boost to its already strong investment performance this year as a result of a deal that will see Eli Lilly buy one of its investee companies, the US biotech ARMO Biosciences. Lilly’s agreed deal to […]
-
02 May 2018 3 min read
BB Biotech and HBMH will take hit on Esperion side-effect scare
BB Biotech and HBMH will take hit on Esperion side-effect scare BB Biotech (BBB) and HBM Healthcare (HBMH) may have to take a hit on their investments in the US biotech Esperion Therapeutics, which has seen its stock fall by 22% today on the back of results from its second pivotal Phase III study assessing […]
-
03 Apr 2018 2 min read
HBM Healthcare to benefit from Homology Medicines IPO
HBM Healthcare to benefit from Homology Medicines IPO Swiss-listed HBM Healthcare (HBMN) is set to receive a modest boost to its NAV following the US initial public offering last week of Homology Medicines (Nasdaq: FIXX), a US gene editing/gene therapy company developing treatments for rare disease. Homology raised a total of $165.6m from an offering of 10.35m shares at $16.00 […]
-
02 Mar 2018 3 min read
Swiss trusts top performers among bio sector specialists in Feb
Swiss trusts top performers among bio sector specialists in Feb – Switzerland’s HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S) were the best performing biotech/pharma specialist investment trusts in February and indeed were the only ones of the 13 monitored by Marten & Co to have recorded any increase in NAV (in sterling terms) in the month. However, […]
-
26 Feb 2018 2 min read
HBM investee ObsEva reports successful trail of IVF drug
HBM investee ObsEva reports successful trail of IVF drug HBM Healthcare Investments (HBMN.S) investee ObsEva (Nasdaq: OBSV) has reported positive results in the Implant2 phase III trial of nolasiban, an oxytocin receptor antagonist, for improving pregnancy rates associated with in-vitro fertilisation (IVF). ObsEva is currently HMB Healthcare’s tenth largest holding, accounting for 2.3% of its […]
-
15 Feb 2018 2 min read
HBM Healthcare reaps $28m profit on sale of TandemLife stake
HBM Healthcare reaps $28m profit on sale of TandemLife stake Swiss-listed HBM Healthcare Investments (HBMN.S) should realise an profit of at least $27.6m on the sale of its holding in the med-tech company TandemLife, as a result of the company’s acquisition by Livanova. HBM Healthcare holds a 16.6% stake in TandemLife, which is carried on […]
-
09 Feb 2018 3 min read
Swiss biotech trusts resilient after recent sell-off
Swiss biotech trusts resilient after recent sell-off – Swiss-listed biotech investment trusts, HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S), have fared by far the best among all the sector specialist closed-end collective vehicles in the wake of the global market sell-off in recent days. All 13 trusts in the group monitored by Marten & Co have seen a fall […]
-
23 Jan 2018 3 min read
HBM Healthcare tops biotech trust league in 2017
HBM Healthcare tops biotech trust league in 2017 Swiss-listed HBM Healthcare Investments (HBMN.S) can claim to have been the best performing biotech-specialist closed-end fund in 2017, according to an analysis by Marten & Co. The CHF1.1bn trust run by Swiss healthcare investment specialist HBM saw its share price rise from CHF99 to CHF134 last year […]
-
19 Dec 2017 2 min read
HBM Healthcare sees healthy NAV rise but remains at a deep discount
HBM Healthcare sees healthy NAV rise but remains at a deep discount Swiss-listed HBM Healthcare Investments (HBMN.S) recorded an impressive 23% rise in NAV and saw a 36% gain in its share price in the 11 months to end November, according to its latest monthly update. However, the trust’s shares currently trade at an 18.5% discount to […]
-
24 Apr 2015 2 min read
Cayenne Trust says considering proposals for future of the company
The Cayenne Trust’s results for the year ended 31 January 2015 have been published. The company’s net asset value total return and share price total return were both 12.1% for the period. This compares to an 11.6% return on the FTSE All-Share Equity Investments Index. The dividend has been increased from 1.2p to 3.8p. The […]